Elevated expression of the metabolic regulator receptor-interacting protein 140 results in cardiac hypertrophy and impaired cardiac function

Cardiovascular Research

Volumn 86, Issue 3, 2010, Pages 443-451

  Fritah, Asma ^a   Steel, Jennifer H ^a   Nichol, Donna ^a   Parker, Nadeene ^b   Williams, Sharron ^a   Price, Anthony ^a   Strauss, Leena ^c   Ryder, Timothy A ^d   Mobberley, Margaret A ^d   Poutanen, Matti ^c   Parker, Malcolm ^a   White, Roger ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF TURKU   (Finland)

^d CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

Cardiac hypertrophy; Mitochondria; Nuclear receptors; RIP140; Transgenic mice

Indexed keywords

CD36 ANTIGEN; CELL NUCLEUS RECEPTOR; CYTOCHROME C OXIDASE; CYTOCHROME OXIDASE VIIA; CYTOCHROME XII; ESTROGEN RECEPTOR; ESTROGEN RELATED RECEPTOR ALPHA; ESTROGEN RELATED RECEPTOR GAMMA; FATTY ACID; FATTY ACID TRANSPORTER; MEDIUM CHAIN ACYL COENZYME A DEHYDROGENASE; MESSENGER RNA; OXYGEN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; RECEPTOR INTERACTING PROTEIN 140; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR A; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVITY; CONTROLLED STUDY; FATTY ACID METABOLISM; FEMALE; GENE EXPRESSION; HEART; HEART DISEASE; HEART FUNCTION; HEART MITOCHONDRION; HEART MUSCLE FIBROSIS; HEART VENTRICLE; HEART VENTRICLE HYPERTROPHY; INTERVENTION STUDY; MALE; MEMBRANE POTENTIAL; MICROSCOPY; MODEL; MORTALITY; MOUSE; NONHUMAN; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TRANSGENIC MOUSE; WESTERN BLOTTING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AGING; ANIMALS; CARDIOMEGALY; ENERGY METABOLISM; FEMALE; FIBROSIS; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORKS; GENOTYPE; HEART ATRIA; HEART VENTRICLES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MICE, TRANSGENIC; MITOCHONDRIA, HEART; MYOCARDIAL CONTRACTION; MYOCARDIUM; NUCLEAR PROTEINS; OXYGEN CONSUMPTION; PHENOTYPE; RNA, MESSENGER; SEX FACTORS;

EID: 77952391461     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvp418     Document Type: Article

References (52)

1. Cavailles V, Dauvois S, L'Horset F, Lopez G, Hoare S, Kushner PJ et al. Nuclear factor RIP140 modulates transcriptional activation by the estrogen receptor. EMBO J 1995; 14:3741-3751.
2. L'Horset F, Dauvois S, Heery DM, Cavailles V, Parker MG. RIP-140 interacts with multiple nuclear receptors by means of two distinct sites. Mol Cell Biol 1996;16: 6029-6036.
3. Treuter E, Albrektsen T, Johansson L, Leers J, Gustafsson JA. A regulatory role for RIP140 in nuclear receptor activation. Mol Endocrinol 1998;12:864-881.
4. White R, Leonardsson G, Rosewell I, Ann Jacobs M, Milligan S, Parker M. The nuclear receptor co-repressor nrip1 (RIP140) is essential for female fertility. Nat Med 2000;6: 1368-1374.
5. Leonardsson G, Steel JH, Christian M, Pocock V, Milligan S, Bell J et al. Nuclear receptor corepressor RIP140 regulates fat accumulation. PNAS 2004;101:8437-8442.
6. Seth A, Steel JH, Nichol D, Pocock V, Kumaran MK, Fritah A et al. The transcriptional corepressor RIP140 regulates oxidative metabolism in skeletal muscle. Cell Metab 2007;6:236-245.
7. Christian M, Kiskinis E, Debevec D, Leonardsson G, White R, Parker MG. RIP140-targeted repression of gene expression in adipocytes. Mol Cell Biol 2005;25: 9383-9391.
8. Christian M, White R, Parker MG. Metabolic regulation by the nuclear receptor cor-epressor RIP140. Trends Endocrinol Metab 2006;17:243-250.
9. Teyssier C, Belguise K, Galtier F, Cavailles V, Chalbos D. Receptor-interacting protein 140 binds c-Jun and inhibits estradiol-induced activator protein-1 activity by reversing glucocorticoid receptor-interacting protein 1 effect. Mol Endocrinol 2003;17:287-299.
10. Castet A, Herledan A, Bonnet S, Jalaguier S, Vanacker JM, Cavailles V. Receptor-interacting protein 140 differentially regulates estrogen receptor-related receptor transactivation depending on target genes. Mol Endocrinol 2006;20:1035-1047.
11. Kumar MB, Tarpey RW, Perdew GH. Differential recruitment of coactivator RIP140 by Ah and estrogen receptors. Absence of a role for LXXLL motifs. J Biol Chem 1999; 274:22155-22164.
12. Zschiedrich I, Hardeland U, Krones-Herzig A, Berriel Diaz M, Vegiopoulos A, Muggenburg J et al. Co-activator function of RIP140 for NFfkappagB/RelA- dependent cytokine gene expression. Blood 2008;112:264-276.
13. Niwa H, Yamamura K, Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 1991;108:193-199.
14. Okabe M, Ikawa M, Kominami K, Nakanishi T, Nishimune Y. 'Green mice' as a source of ubiquitous green cells. FEBS Lett 1997;407:313-319.
15. Burkart EM, Sambandam N, Han X, Gross RW, Courtois M, Gierasch CM et al. Nuclear receptors PPARbeta/delta and PPARalpha direct distinct metabolic regulatory programs in the mouse heart. J Clin Invest 2007;117:3930-3939.
16. Dufour CR, Wilson BJ, Huss JM, Kelly DP, Alaynick WA, Downes M et al. Genome-wide orchestration of cardiac functions by the orphan nuclear receptors ERRalpha and gamma. Cell Metab 2007;5:345-356.
17. Huss JM, Imahashi K, Dufour CR, Weinheimer CJ, Courtois M, Kovacs A et al. The nuclear receptor ERRalpha is required for the bioenergetic and functional adaptation to cardiac pressure overload. Cell Metab 2007;6:25-37.
18. Huss JM, Kelly DP. Nuclear receptor signaling and cardiac energetics. Circ Res 2004;95: 568-578.
19. Kinugawa K, Yonekura K, Ribeiro RC, Eto Y, Aoyagi T, Baxter JD et al. Regulation of thyroid hormone receptor isoforms in physiological and pathological cardiac hypertrophy. Circ Res 2001;89:591-598.
20. Cheng L, Ding G, Qin Q, Huang Y, Lewis W, He N et al. Cardiomyocyte-restricted peroxisome proliferator-activated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nat Med 2004;10:1245-1250.
21. Arany Z, He H, Lin J, Hoyer K, Handschin C, Toka O et al. Transcriptional coactivator PGC-1 alpha controls the energy state and contractile function of cardiac muscle. Cell Metab 2005;1:259-271.
22. Lehman JJ, Barger PM, Kovacs A, Saffitz JE, Medeiros DM, Kelly DP. Peroxisome proliferator-activated receptor gamma coactivator-1 promotes cardiac mitochondrial biogenesis. J Clin Invest 2000;106:847-856.
23. Lehman JJ, Boudina S, Banke NH, Sambandam N, Han X, Young DM et al. The tran-scriptional coactivator PGC-1alpha is essential for maximal and efficient cardiac mito-chondrial fatty acid oxidation and lipid homeostasis. Am J Physiol 2008;106:847-856.
24. Lin J, Handschin C, Spiegelman BM. Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab 2005;1:361-370.
25. Lelliott CJ, Medina-Gomez G, Petrovic N, Kis A, Feldmann HM, Bjursell M et al. Ablation of PGC-1beta results in defective mitochondrial activity, thermogenesis, hepatic function, and cardiac performance. PLoS Biol 2006;4:e369.
26. Taegtmeyer H, Wilson CR, Razeghi P, Sharma S. Metabolic energetics and genetics in the heart. Ann NY Acad Sci 2005;1047:208-218.
27. Djouadi F, Brandt JM, Weinheimer CJ, Leone TC, Gonzalez FJ, Kelly DP. The role of the peroxisome proliferator-activated receptor alpha (PPAR alpha) in the control of cardiac lipid metabolism. Prostaglandins Leukot Essent Fatty Acids 1999;60:339-343.
28. Watanabe K, Fujii H, Takahashi T, Kodama M, Aizawa Y, Ohta Y et al. Constitutive regulation of cardiac fatty acid metabolism through peroxisome proliferator-activated receptor alpha associated with age-dependent cardiactoxicity. J Biol Chem 2000;275: 22293-22299.
29. Gilde AJ, van der Lee KA, Willemsen PH, Chinetti G, van der Leij FR, van der Vusse GJ et al. Peroxisome proliferator-activated receptor (PPAR) alpha and PPAR-beta/delta, but not PPARgamma, modulate the expression of genes involved in cardiac lipid metabolism. Circ Res 2003;92:518-524.
30. Huss JM, Torra IP, Staels B, Giguere V, Kelly DP. Estrogen-related receptor alpha directs peroxisome proliferator-activated receptor alpha signaling in the transcrip-tional control of energy metabolism in cardiac and skeletal muscle. Mol Cell Biol 2004;24:9079-9091.
31. Vikstrom KL, Bohlmeyer T, Factor SM, Leinwand LA. Hypertrophy, pathology, and molecular markers of cardiac pathogenesis. Circ Res 1998;82:773-778.
32. Chien KR, Zhu H, Knowlton KU, Miller-Hance W, van-Bilsen M, O'Brien TX et al. Transcriptional regulation during cardiac growth and development. Ann Rev Physiol 1993;55:77-95. (Pubitemid 23102124)
33. Feldman AM, Ray PE, Silan CM, Mercer JA, Minobe W, Bristow MR. Selective gene expression in failing human heart. Quantification of steady-state levels of messenger RNA in endomyocardial biopsies using the polymerase chain reaction. Circulation 1991;83:1866-1872.
34. Gupta MP. Factors controlling cardiac myosin-isoform shift during hypertrophy and heart failure. J Mol Cell Cardiol 2007;43:388-403.
35. Parker N, Affourtit C, Vidal-Puig A, Brand MD. Energization-dependent endogenous activation of proton conductance in skeletal muscle mitochondria. Biochem J 2008; 412:131-139.
36. Goffart S, von Kleist-Retzow JC, Wiesner RJ. Regulation of mitochondrial proliferation in the heart: power-plant failure contributes to cardiac failure in hypertrophy. Cardi-ovasc Res 2004;64:198-207.
37. Frey N, Katus HA, Olson EN, Hill JA. Hypertrophy of the heart: a new therapeutic target? Circulation 2004;109:1580-1589.
38. Hill JA, Olson EN. Cardiac plasticity. New Engl J Med 2008;358:1370-1380.
39. van Bilsen M. 'Energenetics' of heart failure. Ann NY Acad Sci 2004;1015:238-249.
40. Neubauer S. The failing heart\an engine out of fuel. New Engl J Med 2007;356: 1140-1151.
41. Ventura-Clapier R, Garnier A, Veksler V. Energy metabolism in heart failure. J Physiol 2004;555:1-13.
42. Lewis W, Day BJ, Kohler JJ, Hosseini SH, Chan SS, Green EC et al. Decreased mtDNA, oxidative stress, cardiomyopathy, and death from transgenic cardiac targeted human mutant polymerase gamma. Lab Invest 2007;87:326-335.
43. Luptak I, Balschi JA, Xing Y, Leone TC, Kelly DP, Tian R. Decreased contractile and metabolic reserve in peroxisome proliferator-activated receptor-alpha-null hearts can be rescued by increasing glucose transport and utilization. Circulation 2005;112: 2339-2346.
44. Campbell FM, Kozak R, Wagner A, Altarejos JY, Dyck JR, Belke DD et al. A role for peroxisome proliferator-activated receptor alpha (PPARalpha) in the control of cardiac malonyl-CoA levels: reduced fatty acid oxidation rates and increased glucose oxidation rates in the hearts of mice lacking PPARalpha are associated with higher concentrations of malonyl-CoA and reduced expression of malonyl-CoA dec-arboxylase. J Biol Chem 2002;277:4098-4103.
45. Barish GD, Narkar VA, Evans RM. PPAR delta: a dagger in the heart of the metabolic syndrome. J Clin Invest 2006;116:590-597.
46. Ogata T, Miyauchi T, Sakai S, Takanashi M, Irukayama-Tomobe Y, Yamaguchi I. Myo-cardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-B pathway. J Am Coll Cardiol 2004;43:1481-1488.
47. Teunissen BE, Smeets PJ, Willemsen PH, De Windt LJ, Van der Vusse GJ, Van Bilsen M. Activation of PPARdelta inhibits cardiac fibroblast proliferation and the transdifferentiation into myofibroblasts. Cardiovasc Res 2007;75:519-529.
48. Vuolteenaho O, Ruskoaho H. Gender matters: estrogen protects from cardiac hypertrophy. Trends Endocrinol Metab 2003;14:52-54.
49. Pedram A, Razandi M, Lubahn D, Liu J, Vannan M, Levin ER. Estrogen inhibits cardiac hypertrophy: role of estrogen receptor-beta to inhibit calcineurin. Endocrinology 2008; 149:3361-3369.
50. Cavailles V, Dauvois S, Danielian PS, Parker MG. Interaction of proteins with tran-scriptionally active estrogen receptors. PNAS 1994;91:10009-10013.
51. Handschin C, Spiegelman BM. Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators, energy homeostasis, and metabolism. Endocr Rev 2006; 27:728-735.
52. Lai L, Leone TC, Zechner C, Schaeffer PJ, Kelly SM, Flanagan DP et al. Transcriptional coactivators PGC-1alpha and PGC-lbeta control overlapping programs required for perinatal maturation of the heart. Genes Dev 2008;22:1948-1961.